Browsing by Author Kefford, Richard

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 12 of 12
Issue DateTitleAuthor(s)Citation
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2016The molecular profile of metastatic melanoma in AustraliaCooper, Wendy Anne; Haydu, Lauren; Long, Georgina; Lyle, Megan; Mann, Graham; Menzies, Alexander Maxwel; O'Toole, Sandra; Saw, Robyn; Scolyer, Richard; Spillane, Andrew; Thompson, John; Yu, Bing; Kefford, Richard; Central Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: Pathology; Northern Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: MedicineThe molecular profile of metastatic melanoma in Australia, Pathology, vol.48, 2, 2016,pp 188-193
2017PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitorsCarlino, Matteo; Howle, Julie; Kakavand, Hojabr; Long, Georgina; Menzies, Alexander Maxwel; Pupo, Gulietta; Saw, Robyn; Scolyer, Richard; Thompson, John; Wilmott, James; Yang, Jean Yee Hwa; Kefford, Richard; Rawson, Robert; Rizos, Helen; Westmead Clinical School: Medicine; Westmead Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Westmead Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: Surgery; Mathematics & StatisticsPD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors, Clinical Cancer Research, vol.23, 20, 2017,pp 6054-6061
2017Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysisBoddy, Alan; Carlino, Matteo; Harris, David; Lee, Vincent; Liu, Xiao man; Kefford, Richard; Park, J; Pharmacy; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); PharmacyPharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis, Pigment Cell & Melanoma Research, vol.30, 1, 2017,pp 68-71
2017Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialCarlino, Matteo; Guminski, Alexander; Kong, Benjamin; Lomax, Anna; Long, Georgina; McNeil, Catriona; Menzies, Alexander Maxwel; Atkins, Michael B; Atkinson, Victoria; Cebon, Jonathan Simon; Ebbinghaus, Scot; Fitzharris, Bernie; Hill, A; Hodi, F. Stephen; Hwu, Wen-Jen; Ibrahim, Nageatte; Islam, Mohammed; Jameson, Michael B; Kefford, Richard; Ribas, Antoni; Shu, Xinxin; Srivastava, Archana; Tamjid, Babak; Thompson, John; Westmead Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Office; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Northern Clinical School: Medicine; Central Clinical School: Medicine; Northern Clinical School: MedicineStandard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial, The Lancet Oncology, vol.18, 9, 2017,pp 1202-1210